Skip to main content

Aggregator

Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy

2 weeks 5 days ago
Alzheimer's disease (AD) is the leading cause of dementia and is characterized by progressive amyloid accumulation followed by tau-mediated neurodegeneration. Despite advances in anti-amyloid immunotherapies, important limitations remain, highlighting the need for new therapeutic strategies. Here, we introduce anti-amyloid chimeric antigen receptors expressed in astrocytes (CAR-A) and validate their function in vitro. We show that two CAR-A designs reduce amyloid and associated pathology after...
Yun Chen

MS4A4A and MS4A6A: New targets to enhance microglia protective function in Alzheimer's disease

2 weeks 5 days ago
MS4A4A and MS4A6A are microglia-expressed genes linked to Alzheimer's disease risk. In this issue of Neuron, Rosner et al.¹ show that these proteins cooperatively restrain TREM2 signaling, dampening protective microglial responses and highlighting MS4A inhibition as a potential strategy to rejuvenate the brain's innate immune system in Alzheimer's disease.
David V Hansen

Genetically encoded fluorescent reporters to visualize α-synuclein pathology in live brain

2 weeks 5 days ago
Lewy bodies, a pathological hallmark of Parkinson's disease, are α-synuclein-enriched cytoplasmic inclusions that drive progressive neurodegeneration. A long-standing yet unmet goal has been the visualization of α-synuclein (α-Syn) inclusions in live brain and measurements of their pathological effects on individual neurons. Here, we developed genetically encoded reporters and knock-in mouse lines to achieve this goal. The reporters exhibited a 5-fold increase in fluorescence upon incorporation...
Li Zhang

Trained immunity in neuroinflammation: emerging evidence, clinical perspectives, and future directions

2 weeks 5 days ago
Trained immunity is the ability of the innate immune system to mount a heightened response to an environmental stimulus after a previous encounter with a noxious trigger. This effect is mediated by metabolic rewiring and epigenetic reprogramming in innate immune cells. In the context of neuroinflammation, trained immunity may represent a major contributor to the pathogenesis of neurological diseases, exerting both detrimental and potentially beneficial effects. While the general mechanisms and...
Enis Guso

Early mitophagy activation by Urolithin A prevents, but late activation does not reverse, age-related cognitive impairment

2 weeks 5 days ago
The hippocampus is crucial to learning and memory, functions that decline with age due to impaired mitochondrial bioenergetics and reduced mitophagy, resulting in the accumulation of dysfunctional mitochondria and increased susceptibility to neurodegeneration. Urolithin A (UA), a natural mitophagy activator derived from polyphenols, has demonstrated benefits in Alzheimer's disease models; however, its role in normal aging remains unclear. Here, we investigated whether UA can prevent or reverse...
Claudia Jara

In vitro and in vivo rescue of dopaminergic neurons in Parkinson's disease models after Parkin gene therapy

2 weeks 5 days ago
Young-onset Parkinson's disease (PD), the most common autosomal recessive familial PD, is caused by gene mutations in Parkin (PRKN). These mutations result in Parkin protein loss and reduced enzymatic activity, leading to severe degeneration of dopamine-producing neurons in the substantia nigra pars compacta (SNpc). Adeno-associated virus (AAV) gene therapy can directly address the cause of PRKN-PD by expressing Parkin protein at levels comparable to those observed in healthy humans. AAV9...
Takeshi Hioki

The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial

2 weeks 5 days ago
Triggering receptor expressed on myeloid cells 2 (TREM2) regulates microglial function and is implicated in Alzheimer's disease (AD) pathogenesis. Here we conducted a phase 2, randomized, double-blind, placebo-controlled trial of a humanized TREM2 agonistic monoclonal antibody in 381 participants with early AD. Participants were randomized (1:1:1:1) to receive AL002 (15 mg kg^(-1), 40 mg kg^(-1) or 60 mg kg^(-1)) or placebo intravenously every 4 weeks for 48-96 weeks. AL002 demonstrated...
Catherine J Mummery